future studies are to design a prospective study, include persistence and adherence measures in the study design, and to assess patient outcomes with additional measures such as patient outcomes based on a patient-centered approach and adverse effects.

Disclosure of interest: This literature review was funded by AbbVie Inc.

REFERENCES


Disclosure of Interests: None declared


**AB1224**

IS THERE A NEED TO OPTIMIZE REFERRAL DIAGNOSIS TO A RHEUMATOLOGY DEPARTMENT?:

Tobias Hoffmann, Peter Oelzner, Gunter Wolf, Alexander Pfeil, Jena University Hospital – Friedrich Schiller University Jena, Department of Internal Medicine III, Jena, Germany

Background: The initial visitation of patient suffering from rheumatic disease related symptoms often occurs in absence of a rheumatologist.

Objectives: This study evaluated the following questions: I. Which medical specialists refer patients to a rheumatology department? II. To quantify the accordance of the presumptive diagnosis and the final diagnosis of a patient and a health professional, which may be variable. Therefore, recognition and reporting of adverse events remain relatively haphazard. In this context the presumptive diagnosis of a general practitioner presents a low accordance with the final diagnosis. In this context, general practitioners should achieve a detailed education in the assessment of rheumatic-related symptoms to optimize the dedicated referral to rheumatological departments.

Disclosures of Interest: Tobias Hoffmann: None declared, Peter Oelzner: None declared, Gunter Wolf: None declared, Alexander Pfeil: Grant/Research support from: This study is a part of the Investigator Initiated Study “The quantification of inflammatory related periarticular bone loss in certolizumab pegol treated patients with rheumatoid arthritis” which is funded and supported by UCB Pharma GmbH, Monheim, Germany (number: IIS-2014-101458).


**AB1225**

POSSIBLE EARLY DETECTION OF ADVERSE EVENTS USING REMOTE SYSTEMATIC WEEKLY ELECTRONIC MDHAQ

Theodore Pinicus, Rush University Medical Center, Chicago, United States of America

Background: Adverse events of medications are reported to account for 5% of hospital admissions in the USA, including 10% in the elderly. Warnings from doctors and pharmacies concerning adverse events are given at initiation of new medications, but adverse events often occur between visits and reporting depends primarily on communication between a patient and a health professional, which may be variable. Therefore, recognition and reporting of adverse events remain relatively haphazard. Several reports present strategies for systematic monitoring for adverse events, primarily involving telephone contacts from nurses to patients. A far less expensive systematic approach based on patient self-report using a remote electronic multidimensional health assessment questionnaire
(MDHAQ) 60-symptom checklist may recognize most adverse events of medications.

Objectives: To document recognition of adverse events using a remote weekly electronic MDHAQ completed by patients at home, as a cost-effective approach to reduce their morbidity, costs, and mortality.

Methods: The MDHAQ includes 0-10 scales for physical function, pain, and patient global assessment, compiled into a 0-30 RAPID3, fatigue and painful joint count, to assess treatment efficacy. The MDHAQ also includes a 60-symptom checklist to recognize comorbidities, review of systems, and symptom reduction; this checklist also recognizes adverse events associated with medications. Weekly remote completion of an electronic MDHAQ at home can monitor both efficacy and adverse events.

Results: A flowsheet from a patient with pulmonary fibrosis monitored over 2018 illustrates remote electronic MDHAQ use. At a first visit of 19 Jan, a routine clinic-based MDHAQ indicated RAPID3 of 14/30, fatigue 6/10, and 10 symptoms (Flowsheet). Treatment with low-dose methotrexate and prednisone led to clinical improvement from 19 Jan to 2 Aug, RAPID3 to 3.5, fatigue 2, and 6 symptoms. On 15 Aug, a pulmonologist discontinued prednisone and methotrexate and prescribed pirenidone, an anti-fibrosis agent. A telephone call from the patient on 24 Sep indicated distress. A home-completed remote MDHAQ indicated RAPID3 19.5, fatigue 9, 15 symptoms - 7 not reported on 2 Aug were among 16 adverse events listed for pirenidone. Discontinuation of pirenidone and resumption of prednisone and methotrexate led to improvement of RAPID3 to 4.2; fatigue to 1.0, and resolution of pirenidone-specific symptoms by 24 Dec, documented with weekly remote electronic MDHAQ (Flowsheet). A brief retri of pirenidone indicated an increase of RAPID3 to 6.0, which was discontinued in a timely manner.

78-year-old man monitored over 2018–all data from self-report on MDHAQ – pirenidone highlighted (many entries deleted for space considerations)

Conclusion: Weekly remote electronic MDHAQ monitoring of a high-risk medication for treatment response and adverse events may provide a cost-effective approach to reduce the morbidity and mortality of adverse events, involving about 10 minutes/weekly or 2 hours of patient time over 12 weeks.

Disclose of Interests: None declared


AB1226

ONE YEAR’S RESULTS OF A PROTOCOLIZED HIGH RESOLUTION RHEUMATOLOGY CLINIC

Orlando Pompei Fernández1, Susana Gil Barato2, Belén Álvarez Rodríguez2, Juan Ramón De Dios3, Margarida Vasques Rocha4, Claudia Stoye5, Jaime Calvo2,1
1Araba University Hospital, Rheumatology, Vitoria-Gasteiz, Spain; 2Araba University Hospital, Rheumatology, Vitoria-Gasteiz, Spain

Background: Mechanical musculoskeletal pathologies put high demands on the Public Health Service, as they affect a significant percentage of the population, and cause both temporary and permanent disabilities. The specialised High Resolution Rheumatology Clinic (CAR in Spanish) at our centre started up in October 2017, and focuses on the diagnosis and treatment of pathologies which are fundamentally of a mechanical ethology. The centre covers a population of approximately 328,886 inhabitants (Alava 2018 census).

The aim of our study, carried out at the unit over one year, is to determine the patients’ epidemiological features.

Objectives: • To provide the Primary Care Centres with a “fast-track” and immediate care system in order to guide, diagnose, and treat patients who have worsening acute or chronic mechanical affections to the musculoskeletal system.
• Diagnosis confirmation, request for non-accessible tests, adaptation of treatments mainly for the primary care doctor.
• To speed up and reduce waiting lists, for both inflammatory rheumatic pathologies and mechanical rheumatic pathologies, by establishing new referral guidelines.
• To draw up protocols in agreement with primary care doctors and related specialists.
• To act as a support for other medical services.

Methods: The main services available are those offered mainly to primary care level. There are 3 clinics a week, attending to approximately 30 new patients per week. 1330 patients are included in the study, seen at the High Resolution Rheumatology Clinic (CAR) over 12 consecutive months (November 2017 – 2018), with non-complex regional pathologies and/or soft tissue rheumatism, which are able to be resolved with one or two visits.

Results: 1330 patients were seen, with an average age of 58 ±15.6 years, 64.84% female and 35.36% male, mainly for musculoskeletal ailments. In order of frequency, the visits were for shoulder (25.79%), hip (16.10%), axial skeleton (15.13%), ankle/foot (13.06%), wrist/hand (12.08%), knee (11.21%), and elbow (6.63%). 61.95% of the patients were discharged after the first visit, and one year later, this figure rose to 90.15% of all the patients discharged; only 2.78% made a return visit after being discharged. 22.26% were referred to other services, mainly Traumatology and Orthopaedics (10.53%); Rehabilitation and Physiotherapy (9.72%); and the Pain Management Unit (1.65%). The 3.68% were referred to the usual Rheumatology department. For 52.33% of the patients seen, there was no need to request more than one diagnostic tests, even though 12.41% visited for reasons other than the main one. Moreover, 63.08% received some kind of infiltration injection. The negative point was that 7.89% of the referrals had been made from Primary Care to several specialists at the same time; and 7.98% were consultations regarding traumatic injuries.

Conclusion: Systematising a clinic for mechanical musculoskeletal pathologies which have a high chance of being resolved in the short term, means that the quality of the care given, the waiting times, and the demand on the health service can be improved. Developing these can have important repercussions on waiting lists for other related services, and even for the Rheumatology service itself, allowing more serious cases to be seen earlier. Creating multi-disciplinary units should be encouraged, in order to improve care quality and prevent the various medical services involved from all carrying out fragmented courses of action. New guidelines could be considered, to optimise the care and management of new resources and/or links to other services, as the most prevalent pathologies can be identified.

Most of the patients seen represent the economically active part of the population; there are therefore, repercussions as far as sick leave, disability leave, etc. is concerned.

Disclose of Interests: Orlando Pompei Fernández: None declared, Susana Gil Barato: None declared, Belén Álvarez Rodríguez: None declared, Juan Ramón De Dios: None declared, Margarida Vasques Rocha: None declared, Claudia Stoye: None declared, Jaime Calvo Consultant for: Bristol-Myers Squibb, Janssen, Celgene, Sanofi Genzyme, Speakers bureau: Bristol-Myers Squibb


AB1227

PREFERRED REFERRAL PROTOCOL FOR RECENT ONSET ARTHRITIS IN ADULTS FROM PRIMARY CARE TO RHEUMATOLOGY

Conseluo Ramos Giráldez1, María Espinoza2, Carolina Merino Argüemana3, Patricia Fernández Crespo2, Olga Rusinovich2, Fernando León Vázquez2, José Luis Andrea Sánchez2, Carmen Barbadillo Mateos3,1 Valme Hospital, Rheumatology Unit, Seville, Spain; 2Imanta Sofia Hospital, Rheumatology Unit, Madrid, Spain; 3Puerta de Hierro Majadahonda Hospital, Rheumatology Unit, Madrid, Spain; 4San Juan De La Cruz Primary Care Centre, Pozueclo de Alarcón (Madrid), Spain

Background: The time of rheumatoid arthritis (RA) evolution until treatment begins is key to controlling the disease. Many studies have shown that a prolonged duration of symptoms at the onset of treatment is associated with a more severe course of RA. The time from symptoms onset to first DMARD prescription is >12 weeks in Spain, because of diagnostic delay due to either patient-related factors (delay in consultation), Primary Care Physician (PCP) (delay in citation/referral) or rheumatologist (delay in citation).

Objectives: To evaluate the usefulness of teleconsulting as a preferred referral tool from PCP to Rheumatology for early detection, diagnosis and treatment of inflammatory joint disease in adults, in the health area of a tertiary hospital.

Methods: A preferential referral circuit was established between the PCP and the Rheumatology Service of a tertiary hospital, defining the referral criteria as ‘patient suspected of recent onset arthritis’ (ROA)’: arthritis or inflammatory arthralgia in >1 peripheral joint for >2 weeks with neither traumatic cause nor previous diagnosis of rheumatic disease. PCP performed first assessment, the request for initial tests (blood test including acute phase reactants, rheumatoid factor ± ANA, elemental urine and hands radiography) as well as the referral to Rheumatology with “ROA, suspicion” motive. These consultation requests were cited from the Rheumatology Service within <15 days of receipt.

Before the protocol was established, its functioning was communicated as a face-to-face clinical session: by 2 rheumatologists in a Health Centre (HC) and by 1 PCP in the rest of the HC in the area. A poster was